Statistics on Biotechnology Use  
Results by sector of operation
Sector Companies. Results in biotechnology for main variables and branches of activity 
Units: specified in variables

;Total Companies;Services;Industry and Construction;Agriculture;
No. of companies carrying out R&D in Biotechnology;1,133;722;333;79;
%Companies according to biotechnology used: Genetic code;33;40;19;32;
%Companies according to biotechnology used: Functional units;41;45;38;23;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;24;28;15;26;
%Companies according to biotechnology used: Bioprocesses;50;39;76;35;
%Companies according to biotechnology used: Sub-cellular organisms;6;8;2;0;
%Companies according to biotechnology used: Bio-computing;24;33;9;11;
%Companies according to biotechnology used: Nanobiotechnology;13;16;8;4;
%Companies according to biotechnology used: Other;14;16;8;30;
Companies in which biotechnology activities are: Main and/or exclusive;603;490;99;15;
Companies in which biotechnology activities are: A secondary line of business;173;97;60;16;
Companies in which biotechnology activities are: A tool necessary for production;357;135;175;48;
%Company by field(s) of ultimate application of biotechnology use: Human Health;45;59;24;6;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;18;20;11;27;
%Company by field(s) of ultimate application of biotechnology use: Food products;31;23;51;23;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;22;20;18;62;
%Company by field(s) of ultimate application of biotechnology use: Environment;14;13;15;14;
%Company by field(s) of ultimate application of biotechnology use: Industry;12;14;12;1;
Personnel in R&D in biotechnology (no. of persons);11,510;7,769;3,054;687;
Personnel in R&D in biotechnology (no. of persons): Researchers;6,202;4,554;1,408;241;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;5,308;3,215;1,646;446;
Personnel in R&D in biotechnology (no. of persons): women;6,389;4,518;1,543;328;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;3,304;2,434;754;115;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;3,086;2,084;789;213;
Personnel in R&D in biotechnology (FTE);8,236.9;5,941.7;1,868.5;426.7;
Personnel in R&D in biotechnology (FTE): Researchers;4,596.1;3,468.7;963.3;164.1;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;3,640.8;2,473.0;905.3;262.6;
Personnel in R&D in biotechnology (FTE): women;4,698.5;3,453.0;1,020.7;224.9;
Personnel in R&D in biotechnology (FTE): (women) Researchers;2,512.5;1,878.4;557.4;76.6;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;2,186.0;1,574.5;463.3;148.2;
Internal expenditure on R&D (thousands of euros);769,431;533,657;201,922;33,852;
1) By nature of the expense: Current expenses;719,715;504,270;185,577;29,868;
1.1) Remuneration to researchers;221,447;149,223;64,648;7,576;
1.2) Remuneration to technicians and assistants;122,809;75,033;41,097;6,679;
1.3) Other current expenses;375,459;280,014;79,832;15,614;
2) By nature of the expense: Capital expenses;49,715;29,387;16,345;3,984;
2.1) Land and buildings;9,521;3,329;4,506;1,687;
2.2) Equipment and instruments;30,466;18,712;9,484;2,269;
2.3) Acquisition of specific R&D software;1,810;1,279;508;23;
2.4) Otros productos de propiedad intelectual específicos para I+D;7,919;6,066;1,847;5;
1.1) By origin of the funds: Own funds;490,913;304,305;156,340;30,268;
1.2) By origin of the funds: From companies;82,548;76,853;5,695;0;
1.3) By origin of the funds: Public Administration funds;96,809;83,993;11,520;1,296;
1.4) By origin of the funds: From Universities;197;185;12;0;
1.5) By origin of the funds: From non profit private institutions;4,766;4,766;0;0;
1.6) By origin of the funds: Foreign funds;94,197;63,555;28,355;2,288;
Purchase of R&D services in biotechnology (thousands of euros);120,281;60,387;59,506;389;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;69,564;15,873;53,360;331;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;50,718;44,514;6,146;58;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;45;54;27;41;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;12;11;16;13;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;16;16;16;15;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;14;15;12;9;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;16;19;11;14;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;18;21;13;14;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;15;16;13;20;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;37;38;33;37;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;52;56;42;57;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;20;21;15;29;
% Companies that have requested biotechnology patents in Biotechnology;15;17;11;6;
Number of patents requested;681;493;154;34;
% Companies with income of an international origin related to biotechnological activities;24.3;29.0;18.4;6.4;
% Turnover representing income of an international origin related to biotechnological activities;1.00;4.00;1.00;0.00;
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;59.60;46.80;62.90;94.50;
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;40.40;53.20;37.10;5.50;
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;80.40;69.20;83.40;99.30;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;16.50;17.00;16.40;0.00;
% Income of an international origin related with activities according to the classification: Operating source abroad;2.20;9.70;0.20;0.70;
% Income of an international origin related with activities according to the classification: Other;0.90;4.10;0.00;0.00;
Notes:
1) '.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Source: National Statistics Institute